Reappraisal of Cisplatin vs Carboplatin Treatment for Solid Tumors

In this umbrella meta-analysis comparing cisplatin- and carboplatin-based chemotherapy, the findings clarified the certainty of evidence regarding their comparative efficacy and safety. High-certainty findings were confined to urothelial and ovarian cancers. For most other tumor types, particularly for survival outcomes, estimates suggested no meaningful differences, with moderate to low certainty, highlighting important gaps in high-level evidence.

Corresponding Author: Pablo Jiménez-Labaig, MD, Head and Neck Unit, The Royal Marsden NHS Foundation Trust, 203 Fulham Rd, SW3 6JJ London, United Kingdom (pablojimenez.pjl@gmail.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.